Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Women's Health Mental Health / Psychiatry Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT06903442

Developing a Brief Intervention to Communicate Cardiovascular Risk to Patients Presenting to the Emergency Department With Chest Pain: a Co-Production Approach. Phase 2.

Developing a Brief Intervention to Communicate Cardiovascular Risk to Patients Presenting to the Emergency Department With Chest Pain: a Co-Production Approach. Phase 2. — Recruiting • Non-phase study…

📅 03 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06903442
Sponsor
University of Edinburgh
Start
2025-08-25
ClinicaliQ Trial Snapshot
  • Developing a Brief Intervention to Communicate Cardiovascular Risk to Patients Presenting to the Emergency Department With Chest Pain: a Co-Production Approach. Phase 2. — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06903442.
  • Sponsor: University of Edinburgh.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Some patients who come to the emergency department with chest pain and have not had a heart attack, are at an increased risk of having a heart attack in the future. The investigators know this by taking a blood test (troponin) which looks at damage to the patient's heart. These patients are often sent home from hospital with no information about their risk of heart disease. A patient survey revealed that patients in the emergency department would like to receive more information about heart disease. In this study the investigators…

Eligibility Snapshot
  • : * Patients who present to the Emergency Department with symptoms suggestive of acute coronary syndrome * A maximum high-sensitivity cardiac troponin I between 5 ng/L and the sex-specific 99th centile. * Resides in Scotland and has a CHI number * Adults aged 18 and over * No history of cardiovascular disease * At least 1 modifiable cardiovascular risk factor: current smoker, hypertension (140/90 mmHg), hypercholesterolaemia (>6.0 mmol/L), overweight and obesity (BMI >25), hyperglycaemia or diabetes mellitus. * Patients who are able to provide informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
CPD
Cardiovascular Risk Reduction — Latest Evidence 2024
Cardiology / Cardiovascular · 1.5 CPD hours · 25 Mar 2026
Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification. Apply statin, ezetimibe, PCSK9 inhibitor and inclisiran pathways in…
Complete CPD →
Guideline
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Cardiology / Cardiovascular · 27 Mar 2026
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year…
View guideline →
Clinical Brief
Checks reveal young women with deadly ‘silent’ heart risk
Cardiology / Cardiovascular · BBC Health · 31 May 2026
Young women are at significant risk of sudden cardiac death from silent cardiac conditions, challenging the stereotype that this is primarily an…
View brief →
Guideline
2023 ESC Guidelines on the Management of Endocarditis
Cardiology / Cardiovascular · 30 Mar 2026
Covers diagnostic criteria for infective endocarditis (Duke criteria) and appropriate imaging modalities • Provides antimicrobial treatment recommendations based on causative organisms and…
View guideline →